Madrigal poised to enter European MASH market after CHMP endorsement
Madrigal Pharmaceuticals has moved one step closer to marketing the first treatment for metabolic dysfunction-associated steatohepatitis (MASH) in Europe after …
Madrigal Pharmaceuticals has moved one step closer to marketing the first treatment for metabolic dysfunction-associated steatohepatitis (MASH) in Europe after …
Many biotechnology companies are navigating the various obstacles prevalent within the pharmaceutical industry with the implementation of artificial intelligence (AI) …
One of the key advantages of blockchain is that it removes the need for patients to provide the same information …
Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the …
The departure of the US Food and Drug Administration’s (FDA) cell and gene therapy director and deputy director fuels ongoing …
The government of New South Wales (NSW), Australia, has announced an investment of A$20.7m ($13.39m) in access to life-changing therapies …
The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine …
Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value …
While the outlook for vaccines in the US looks bleak under the current administration, the UK Government is pressing ahead …
US-based Actio Biosciences has closed a Series B financing round, raising $66m to advance the genetics-driven small molecule therapeutics pipeline …
BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory …
In a final blow to Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) UK reimbursement prospects, the National Institute for …
Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to advance its portfolio of next-generation therapies …
The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) …
With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics. At …